Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion Reports Q3 2024 Preliminary Separate Revenue of KRW 1.04T and Operating Profit of KRW 461.7B (068270)

Posted on November 8, 2024July 16, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion Reports Q3 2024 Preliminary Separate Revenue of KRW 1.04T and Operating Profit of KRW 461.7B (068270)

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-11-08

Disclosure Type: Preliminary Earnings Release (Separate) (Fair Disclosure)

💡 3-Second Summary

On a separate basis, Celltrion’s preliminary Q3 2024 revenue reached KRW 1.04T, up 73.32% year-over-year, while operating profit rose 74.76% year-over-year to KRW 461.7B, demonstrating robust financial growth.

📊 1. [Key Disclosure Content & Major Financial Figures Summary]

  • Q3 (Current Quarter) Earnings & Growth Rates (Unit: KRW Million, %):
    • Revenue: KRW 1,039,932 million (Quarter-over-Quarter: +6.86% / Year-over-Year: +73.32%)
    • Operating Profit: KRW 461,652 million (Quarter-over-Quarter: +47.47% / Year-over-Year: +74.76%)
    • Income Before Income Taxes: KRW 430,784 million (Quarter-over-Quarter: +40.71% / Year-over-Year: +51.24%)
    • Net Income: KRW 320,716 million (Quarter-over-Quarter: +31.11% / Year-over-Year: +43.91%)
  • Q3 Cumulative (YTD) Earnings & Growth Rates:
    • Cumulative Revenue: KRW 2,651,375 million (Year-over-Year: +70.12%)
    • Cumulative Operating Profit: KRW 803,493 million (Year-over-Year: +31.15%)
    • Cumulative Income Before Income Taxes: KRW 786,264 million (Year-over-Year: +16.41%)
    • Cumulative Net Income: KRW 626,263 million (Year-over-Year: +17.13%)
  • Disclosure Information Details:
    • Date and Provider: November 8, 2024 / Celltrion IR Team
    • Target Audience: Domestic and international investors, media outlets, etc.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This filing is a fair disclosure presenting Celltrion’s preliminary separate financial results for the third quarter and cumulative nine-month period of 2024, prior to the completion of the external audit.

From a financial perspective, strong upward momentum is verified across both revenue and profitability indicators. Third-quarter separate revenue (approx. KRW 1.04T) increased by 6.86% quarter-over-quarter and 73.32% year-over-year, contributing to a year-to-date cumulative revenue increase of 70.12% (approx. KRW 2.65T). Profitability metrics also performed solidly, with Q3 operating profit (approx. KRW 461.7B) rising 47.47% quarter-over-quarter and 74.76% year-over-year. Cumulative operating profit (approx. KRW 803.5B) grew by 31.15% compared to the same YTD period in 2023. Separate net income also maintained an upward trajectory across both quarterly and cumulative measures. These preliminary calculations are subject to change pending the final audited outcomes from the external auditor.

📝 Editor’s Comment (by K-STOCK Editor)

This fair disclosure registers preliminary, non-audited separate financial results for the third quarter of 2024 to provide timely marketplace communication. The central established fact is that both quarterly and cumulative operating and net profit figures have demonstrated double-digit percentage growth year-over-year, alongside substantial revenue expansion.

Investors must recognize that these metrics are compiled under “separate financial statements” rather than consolidated results, and they represent unaudited internal calculations that are not finalized. The figures remain subject to adjustments once the external auditor completes the official review and finalizes the quarterly accounts. Additionally, this specific filing outlines only separate summary totals and does not break down product-specific sales, research and development costs, or operational expenditure categories.

Consequently, the objective checkpoints for investors to monitor going forward are twofold: first, the official publication of the finalized “Quarterly Report,” verifying whether any discrepancies exist between these separate preliminary figures and the audited separate financial statements; and second, the subsequent verification of detailed strategic drivers and product pipelines in the official IR materials published on the corporate website. Cross-referencing these finalized documents is the necessary pathway to verifying the company’s true financial performance.

📢 Disclaimer & Source Information

Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion Reports Q3 2024 Preliminary Revenue of KRW 881.9B and Operating Profit of KRW 207.7B (068270)
Next Post: [Disclosure] Alteogen(196170) Anticipated for ‘Investment Warning’ Designation and Designated as ‘Investment Caution’ Stock Due to Over 200% Surge in a Year

Related Posts

[Disclosure] Jeju Semiconductor (080220) Posts $162.3B KRW Revenue for FY2024; Top-line Expands 11.2% Driven by High-Premium Shipments Semiconductors
[Disclosure] Alteogen (196170) Clarifies Media Report on ‘KRW 200B RCPS Issuance and Shinhan Securities as Lead Manager’: “Under Consideration But Unconfirmed; No Lead Manager Contract Signed” Disclosures
[Disclosure] Samsung Electronics (005930) Posts Monumental Q2 Operating Profit of KRW 89.4T, Skyrocketing 1,810% YoY in Massive Earnings Surprise Semiconductors
[Disclosure] Samsung Electro-Mechanics (009150) to Unveil FY2023 Earnings on Jan 31… Will It Signal a Global Tech Rebound? Semiconductors
[Disclosure] HANMI Semiconductor (042700) Secures New Incheon Factory Land and Building for 9.8 Billion KRW – Direct Capacity Expansion to Support Surging HBM TC Bonder Demand Semiconductors
[Disclosure] Celltrion (068270), Secures FDA Phase 3 Clinical Trial Application Approval for CT-P13 SC (Zymfentra) in Rheumatoid Arthritis Patients Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme